Abstract:Leprosy, or Hansen's disease, brings challenges with type 1 and type 2 reactions, linked to immune responses against Mycobacterium leprae antigens. Type 1 reactions, with intensified Th1 response, affect 61% of patients, while type 2 reactions, involving immune complexes, occur in 12.2% [1]. Managing neural and systemic complications relies on prednisone, a potent glucocorticoid known for its anti-inflammatory properties targeting pro-inflammatory cytokines like IL-2 and TNF-α [2]. In Brazil, corticosteroid therapy for type 1 leprosy reaction typically begins with oral prednisone at 1 mg/kg/day, decreasing by about 10 mg every 15 days until reaching 20 mg/day. From there, a reduction of 5 mg every 15 days is recommended until it drops to 5 mg/day. Maintaining this dosage for 15 consecutive days is suggested before transitioning to 5 mg/day on alternate days for another 15 days. Thus, the entire treatment lasts around 150 days (or about 5 months) [3]. Exogenous glucocorticoid exposure elevates blood glucose levels in both normal individuals and those with preexisting diabetes mellitus, leading to prediabetes, glucocorticoid-induced diabetes mellitus (GIDM), and steroid-induced hyperglycemia [4]. Higher cumulative doses exceeding 5 to 20 mg/day pose a risk for hyperglycemia [5,6]. A previous study noted dose-related type 2 diabetes risks linked to glucocorticoids, especially in immune-mediated inflammatory conditions. It found a 5% increase in diabetes risk with prednisolone doses ≥25 mg, reinforcing the dose-response relationship [7]. Before diabetes onset and hyperglycemia, prediabetes, marked by impaired glucose tolerance (IGT) and/or fasting glucose, occurs [8]. The impaired fasting glucose (IFG), with values ranging from 100 to 125 mg/dL (5.6 to 6.9 mmol/L), is identified using the fasting plasma glucose (FPG) test, which serves as a crucial initial screening tool for both diabetes and prediabetes [9]. IGT is diagnosed when plasma glucose levels range from 140 to 199 mg/dL (7.8 to 11.0 mmol/L) 2 h after ingesting a 75 g oral glucose solution, as measured by the oral glucose tolerance test (OGTT). This test is more comprehensive and is commonly employed in diagnosing diabetes and gestational diabetes [9]. The definition of GIDM involves abnormal blood glucose levels in individuals without preexisting diabetes, presenting challenges in detection and potentially leading to underestimation in clinical practice [3]. The complexity in diagnosing GIDM arises from the choice of diagnostic test, with physicians frequently favoring the FPG test over the OGTT that exhibits better performance in assessing the impact of glucocorticoids on postprandial glycemia [10]. In the context of leprosy reactions, the glycated hemoglobin test (HbA1c) serves as an indicator of long-term glycemic control, routinely accompanied by a hemogram (red blood cell count) for a comprehensive assessment and precise interpretation of diabetes, particularly in patients with conditions such as anemia, which may be associated with increased HbA1c levels [9–11]. Moreover, for patients on prednisone, requesting serum lipase and amylase tests is paramount. Low levels of these enzymes in diabetes patients correlate with elevated blood glucose levels due to impaired insulin action, stemming from insulin resistance or inadequate insulin secretion. Reduced levels of amylase and lipase are associated with both type 1 and type 2 diabetes mellitus, metabolic syndrome, and excess adiposity [12]. In this context, for both diagnosing GIDM and managing leprosy reaction, capillary blood glucose monitoring is crucial. For patients without preexisting diabetes, monitoring blood glucose once daily before lunch or the evening meal, or 1 to 2 h after these meals is preferable. However, for those already diagnosed with diabetes, monitoring blood glucose up to 4 times daily is recommended—before and after meals, as well as before bedtime. This practice is advised regardless of the level of diabetes control after 2 h [5,13]. Despite the prevalent nature of leprosy and its associated reactions, a significant data void exists, particularly concerning patients undergoing corticoid therapy in endemic regions. Varied incidence rates of prediabetes and GIDM, as highlighted by existing studies, underscore the pressing need for a standardized protocol to navigate the complexities of managing patients on prolonged steroid regimens.

HIGH-DOSE GLUCOCORTICOID TREATMENT DOES NOT INDUCE SEVERE HYPERGLYCEMIA IN YOUNG PATIENTS WITH AUTOIMMUNE DISEASES BY CGMS

Glucocorticoid-Induced Hyperglycemia: A Neglected Problem

Hyperglycemia Induced by Glucocorticoids in Nondiabetic Patients: a Meta-Analysis.

AB1143 BURDEN OF GLUCOCORTICOIDS AMONG RHEUMATOID ARTHRITIS PATIENTS AT DIFFERENT STAGES OF DISEASE-MODIFYING ANTIRHEUMATIC DRUG MANAGEMENT

Glucose metabolism profile recorded by flash glucose monitoring system in patients with hypopituitarism during prednisone replacement

High Frequency of Severe Hyperglycemia Observed During Intensive Hematologic Care: A Prospective Study Using Continuous Glucose Monitoring

Glucocorticoid-induced hyperglycemia and diabetes: Practical points

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.

[Side Effects of Glucocorticosteroids in the Management of 1291 Patients of SARS].

1386-P: Confirmation of the Criteria for Insulin Administration at the Start of Steroid Therapy

A comparative study on the effect of glucose of different dose methylprednisolone therapies in the treatment of theumatoid diseases

Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases

Effect of Recombinant Human Growth Hormone on Glucose Metabolism in Children with Growth Hormone Deficiency

[Diagnosis and therapy of steroid-induced hyperglycemia based on literature reports]

Development and validation of a predictive scoring system for hypoglycaemic agents for optimal control of blood glucose during glucocorticoid therapy

Management of Glucocorticoid-Induced Hyperglycemia in Cancer Patients: A Feasibility Study

The influence of glucose metabolism and its mechanism in patients with thyroid associated ophthalmopathy treated with high-dose glucocorticoid

Is there a lack of a glucose monitoring and management protocol for preventing hyperglycemia and glucocorticoid-induced diabetes mellitus in leprosy reactions?

New insights on hyperglycemia in 17-hydroxylase/17,20-lyase deficiency

Association of clinical, imaging and laboratory parameters with adverse effects of glucocorticoid therapy in patients with giant cell arteritis

Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?